BBIO | Bridgebio pharma inc - Stock Value & PE Ratio Analysis

3

24

15

Limited Growth

AI analysis rates BBIO with a lower value score of 2.
It is mainly due to unstable operating cash flow, along with potential value may be lower.
Over the past 3 months, BBIO has maintained a consecutive value rating of 2.0, close to the rating of 1.9 over the past 3 years, indicating low growth opportunities for enterprise value.
Compared to all stocks in the Health Care sector, BBIO has a medium value rating.

BBIO Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/05/03 (Weekly Update)

BBIO Financial Forecast

Unit : USD

Update to 2025/5/4 (Quarterly Update)

BBIO Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	-0.88	-1,660%	-12%	116.63M	-44.8%	70.5%	-4,506.1%
2024Q3	-1.31	-36.5%	20.2%	5.88M	237.1%	45.6%	-5,931.2%
2024Q2	-0.86	20.4%	-16.5%	2.73M	-33.2%	-95.9%	-3,388.2%
2024Q1	-1.02	-4.1%	-6.4%	2.17M	32.1%	-39.3%	-16.7%
2023Q4	-0.05	94.6%	-87.5%	211.12M	11,461.9%	1,404.8%	-9,636%

Update to 2025/5/9 (Quarterly Update)

BBIO Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

BBIO Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of BBIO from 2019/06 till Now

-
Cumulative Return: -
Annual Return: -
Volatility: -
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from June, 2019 to May, 2025. (Total Trades: 0)